Acetylon begins study of drug candidate for multiple myeloma

09/22/2011 | Mass High Tech (Boston)

Acetylon Pharmaceuticals initiated a Phase I-IIa clinical study of ACY-1215, a drug candidate for relapsed and relapsed-refractory multiple myeloma. Phase I tests the class 2 histone deacetylase inhibitor as a treatment alone and in combination with standard therapies. In Phase IIa, researchers will evaluate the cancer's response to the drug.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC